Our kit is an innovative, improved, and re-designed version of the WHO-recommended Charité, Berlin protocol, along with a newly designed differential test distinguishing between SARS-CoV-2, IAV and IBV.
The kit contains one set of primers and hydrolysis probes (TaqMan®) targeting either the SARS-CoV-2 specific E gene or part of segment 2, encoding the PB1 subunit of IAV. The second set of primers and hydrolysis probes (TaqMan®) is designed to detect the SARS- CoV-2 specific RdRP gene and a part of segment 3, encoding the PA subunit of IBV. In addition, both sets allow the detection of the human RNase P transcript. The TaqMan® probes for E and RdRP gene are conjugated to FAM, the TaqMan® probes for IAV and IBV are conjugated to YY, and the TaqMan® probe for RNase P is conjugated to Cy5. This enables multiplexed detection of SARS- CoV-2, IAV, IBV and human RNase P, which serves as an internal control to validate proper sample collection, RNA extraction, and performance of the test.
The kit is intended exclusively for use in a diagnostic laboratory with the appropriate equipment, safety standards and properly trained personnel. One package of the kit is sufficient for 400 testing reactions. This kit offers flexibility in testing by permitting either screening using two sets of primers and probes (200 screening tests for SARS-CoV-2_E/IAV/RNase P detection and 200 tests for SARS-CoV-2_RdRP/IBV/RNase P detection) or combining the two sets into one multiplexed reaction that can be exclusively used for 400 general screening tests detecting SARS-CoV-2 and flu in general.
